Inebilizumab (indication: neuromyelitis optica spectrum disorders (NMOSD) anti-aquasporin-4 immunoglobulin G (AQP4-IgG) seropositive patients))

Subject:

• Active Sustance: Inebilizumab
• Name: Uplizna®
• Therapeutic area: Neuromyelitis optica spectrum disorders (NMOSD)
• Pharmaceutical company: Horizon Therapeutics GmbH

Time table:

• Start: 01.08.2022
• Final decision by G-BA: 19.01.2023

Final decision:

• No additional benefit proved